Adjusted EBITDA of $69.3 million was also at the upper end of the guidance range, representing a margin of 11%.
BetterHelp adjusted EBITDA was $11.9 million with a margin of 4.9%, in the upper half of guidance but down year-over-year due to lower revenue and investments in insurance initiative.
BetterHelp average paying users declined by roughly 9,000 sequentially to 388,000, 5% lower year-over-year.
BetterHelp segment revenue was $240.4 million, up slightly sequentially and just above midpoint of guidance.
Chronic care program enrollment at quarter end was 1.12 million, down versus the first quarter due to a contract loss, but underlying enrollment would have increased by a low single-digit percentage excluding that impact.
Ended quarter with $680 million in cash and cash equivalents after retiring $551 million in convertible senior notes.
Free cash flow was $61 million in the second quarter, slightly ahead of the prior year period, with year-to-date free cash flow up by $11 million compared to last year.
Integrated Care adjusted EBITDA was $57.5 million, margin of 14.7%, at the high end of guidance but down from 17% prior year due to prior year tailwinds.
Integrated Care segment revenue of $391.5 million increased 3.7% over the prior year period and exceeded the high end of guidance.
Net loss per share was $0.19, compared to a net loss per share of $4.92 in the second quarter of 2024, which included a $4.64 related to a pretax noncash goodwill impairment charge.
Second quarter consolidated revenue was $631.9 million, near the high end of the guidance range and down 1.6% year-over-year, driven by a decline at BetterHelp, offset to some extent by growth in Integrated Care revenues.
U.S. Integrated Care segment membership was 102.4 million members, up 11% year-over-year.
U.S. Integrated Care virtual visit volume increased by 6% versus the prior year period.
Adjusted EBITDA margin expanded by approximately 260 basis points year-over-year to 12.3%.
Balance sheet remains strong with $550 million in cash and no debt.
Free cash flow was $15 million for the quarter, driven by improved working capital and reduced accounts receivable.
Multiomics gross margin declined 500 basis points to 42.6%, due to product mix, lower volume in Sanger Sequencing and Gene Synthesis, and nonrecurring items.
Multiomics segment revenue was $66 million, up 4% reported and 3% organic, driven by next-generation sequencing growth and large customer deals.
Non-GAAP EPS for the quarter was $0.19.
Non-GAAP gross margin improved to 48.5%, up 180 basis points year-over-year, driven by favorable sales mix and operational efficiencies.
Q3 revenue totaled $144 million, flat year-over-year on a reported basis and down 2% organically.
Sample Management Solutions (SMS) revenue was $78 million, down 4% reported and 6% organic, impacted by softer bookings and timing delays.
SMS segment gross margin increased 760 basis points to 53.6%, reflecting favorable product mix and cost management.
Capital position remains strong with $5.4 billion in cash and investments and $579 million in excess capital at insurance subsidiaries.
Loss from operations was $230 million in Q2, a $298 million decrease year-over-year; adjusted EBITDA loss was $199 million, a $304 million decrease year-over-year.
Membership grew 28% year-over-year to over 2 million members, supported by strong retention and SEP additions.
Oscar Health reported Q2 2025 total revenue of $2.9 billion, a 29% year-over-year increase driven by higher membership.
SG&A expense ratio improved by 90 basis points year-over-year to 18.7%, driven by lower exchange fee rates and fixed cost leverage.
The medical loss ratio (MLR) increased 12 points year-over-year to 91.1%, impacted by a $316 million increase in risk adjustment payable due to higher market morbidity.
Adjusted EBITDA grew 5.2% to $114 million, representing 8.1% of net revenue, and adjusted EPS increased 10.8% to $0.41.
Cash flow from operations exceeded $90 million in the quarter, with expectations to generate over $320 million for the full year.
Gross profit was $269 million, up almost 8% versus the prior year, despite gross margin rate pressure from lower-margin limited distribution and rare and orphan therapies.
Option Care Health delivered a strong second quarter with 15% revenue growth year-over-year, driven by mid-teens growth in both acute and chronic therapy portfolios.
The company repurchased $50 million in shares during the quarter, reflecting confidence in the business and its long-term potential.
Adjusted EBITDA was $327.6 million or 28.3% of revenue, consistent with the prior year quarter.
Cash and cash equivalents stood at approximately $2.9 billion, supporting financial flexibility.
DexCom reported second quarter 2025 worldwide revenue of $1.16 billion, a 15% increase compared to $1 billion in Q2 2024, with U.S. revenue at $841 million (up 15%) and international revenue at $316 million (up 16%).
Gross profit was $695.9 million or 60.1% of revenue, down from 63.5% in Q2 2024, impacted by investments in expedited shipping and supply chain stabilization.
Net income was $192.8 million or $0.48 per share.
Operating expenses increased to $474.1 million from $442.7 million in Q2 2024, with operating income at $221.8 million or 19.2% of revenue.
Dafinchi